Search

for
Search:

Glossary Pegylated Interferon

modified interferon with polyethylene glycol for prolonged therapeutic effect

Pegylated Interferon, often abbreviated as PEG-IFN, is a modified form of interferon used to treat certain viral infections and cancers. The "pegylation" process involves attaching polyethylene glycol (PEG) molecules to the interferon, which helps to prolong its presence in the bloodstream, reduce the frequency of dosing, and minimize side effects. This modification enhances the therapeutic efficacy and patient compliance compared to standard interferon treatments.

Related Terms

Research

5 / 416 results

research Pegylated-interferon-α_2ain clinical practice: how to manage patients suffering from side effects

17 citations , February 2011 in “Expert Opinion on Drug Safety”

This review discusses adverse effects associated with pegylated IFN therapy for chronic hepatitis C and highlights the potential of new antiviral drugs to reduce side effects and improve treatment adherence, but reports no new clinical results.

research Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C

17 citations , January 2011 in “The Korean Journal of Hepatology”

This case report details an occurrence of Vogt-Koyanagi-Harada disease during pegylated interferon-α2b and ribavirin therapy for chronic hepatitis C.

research Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C

11 citations , April 2014 in “Journal of Clinical Virology”

This study found that dermatological adverse events from interferon-alpha/ribavirin treatment for chronic hepatitis C are associated with factors like older age, pre-existing skin conditions, cirrhosis, and the use of pegylated interferon formulations.

research Exacerbation of alopecia areata during pegylated interferon alpha-2b and ribavirin therapy, possibly due to the collapse of hair follicle immune privilege

10 citations , September 2014 in “European Journal of Dermatology”

This case report describes a 29-year-old woman with longstanding alopecia areata who experienced improvement in her scalp hair loss after 7 years of topical treatment with squaric acid dibutylester.

research Irreversible alopecia universalis during treatment with pegylated interferon-ribavirin for chronic hepatitis C virus infection: Case report and published work review

9 citations , November 2012 in “Hepatology Research”

This case study reports the first instance of irreversible alopecia universalis occurring during pegylated interferon-ribavirin therapy in a man with hepatitis C infection, without evidence of immunological or thyroid disorders.

View more "pegylated interferon" in research →

Learn

— no results

Try a deeper search in learn →

Community Join

— no results

Try a deeper search in community →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →